We modeled BRAFV600E and NRAS-mutant tumors, which form most patient cutaneous primary melanomas in the clinic (43), and considered a range of further molecular alterations, namely, MITF status, loss of PTEN, presence of BRAFV600E, and loss of CDKN2A. The gene discussed is CDKN2A; the disease is melanoma.